20876-30-6

Basic information

• Product Name: (4-METHOXY-2-NITRO-PHENYL)-ACETIC ACID
• Synonyms: (4-METHOXY-2-NITRO-PHENYL)-ACETIC ACID;(2-Nitro-4-Methoxyphenyl)acetic acid;4-Methoxy-2-nitro-benzeneacetic acid;2-(4-Methoxy-2-nitrophenyl)acetic acid
• CAS NO: 20876-30-6
• Molecular Formula: C₉H₉NO₅
• Molecular Weight: 211.17
• Mol File: 20876-30-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 396 °C at 760 mmHg
• Flash Point: 193.3 °C
• Appearance: /
• Density: 1.382 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (4-METHOXY-2-NITRO-PHENYL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHOXY-2-NITRO-PHENYL)-ACETIC ACID(20876-30-6)
• EPA Substance Registry System: (4-METHOXY-2-NITRO-PHENYL)-ACETIC ACID(20876-30-6)

Safety Data

• Hazardous Substances Data: 20876-30-6(Hazardous Substances Data)

Usage

General Description

(4-Methoxy-2-nitro-phenyl)-acetic acid is a chemical compound with the molecular formula C9H9NO5. It is a yellowish powder that is used in the pharmaceutical and chemical industries as an intermediate in the synthesis of various organic compounds. (4-METHOXY-2-NITRO-PHENYL)-ACETIC ACID is known for its anti-inflammatory and analgesic properties, making it a valuable ingredient in the development of new drugs for pain relief and inflammation treatment. Its chemical structure contains a nitro group and a methoxy group, which contribute to its pharmacological properties and make it an important compound for further research and potential use in medicinal applications.

Upstream product

• 16792-46-4 (4-methoxy-2-nitro-phenyl)-pyruvic acid 
• 17484-36-5 4-Methyl-3-nitroanisole 
• 95-92-1 oxalic acid diethyl ester 
• 7722-84-1 dihydrogen peroxide 
• 105003-90-5 (4-methoxy-2-nitro-phenyl)-acetonitrile 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 2042-14-0 4-methyl-5-nitrophenol 
• 10565-15-8 diethyl 2-(4-methoxy-2-nitrophenyl)malonate 
• 65547-98-0 ethyl 2-cyano-2-(4-methoxy-2-nitrophenyl)acetate 

Downstream Products

• 873421-69-3 (4-methoxy-2-nitro-phenyl)-acetic acid-(3,4-dimethoxy-phenethylamide) 
• 332150-57-9 1-(2,4-dihydroxy-phenyl)-2-(4-methoxy-2-nitro-phenyl)-ethanone 
• 332150-59-1 7-hydroxy-3-(4-methoxy-2-nitro-phenyl)-chromen-4-one 
• 746621-69-2 3-(4-methoxy-2-nitro-phenyl)-7-(2-piperidin-1-yl-ethoxy)-chromen-4-one 
• 109932-73-2 6,7-dimethoxy-1-(4-methoxy-2-nitro-benzyl)-3,4-dihydro-isoquinoline 
• 7699-19-6 6-methoxyoxindole 
• 1050514-02-7 2-(4-methoxy-2-nitrophenyl)ethanol 
• 1196872-67-9 tert-butyl (4-methoxy-2-nitrophenyl)acetate 
• 1334784-89-2 (2-acetylamino-4-methoxy-phenyl)-acetic acid methyl ester 
• 1334784-90-5 (2-acetylamino-4-methoxy-phenyl)-acetic acid 
• 90923-03-8 (4-methoxy-2-nitro-phenyl)-acetic acid methyl ester 
• 1050514-10-7 1-(2-bromoethyl)-4-methoxy-2-nitrobenzene 
• 1050514-11-8 4-methoxy-1-[2-(methylthio)ethyl]-2-nitrobenzene 
• 1050514-03-8 4-methoxy-1-(2-methoxyethyl)-2-nitrobenzene 

Relevant articles and documents

2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES

The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

An aminoisoflavone-salicyloylindole ring transformation

A series of 2′-nitroisoflavones 8-10, 15, 22, 27 and 28 was prepared via the (2-nitro-phenyl)-acetic acids 1, 13, 19 and 25. In order to obtain the corresponding 2′-aminoisoflavones the reduction of 8-10, 15, 22, 27 and 28 was undertaken. Surprisingly, new 3-salicyloylindoles instead of the expected 2′-aminoisoflavones were the main reduction products. In the following paper the preparation of the 2′-nitroisoflavones 8-10, 15, 22, 27 and 28 as well as the reduction experiments obtaining the 2′-aminoisoflavones 33 and 35 and the 3-salicyloylindoles 29-32, 34 and 36 will be described. Furthermore, a possible mechanism responsible for the formation of the 3-salicyloylindoles from 2′-nitroisoflavones under reductive conditions will be discussed.